Novel treatments for head and neck squamous cell carcinoma: Preclinical identification and clinical investigation

Future Oncology

Volumn 10, Issue 6, 2014, Pages 1065-1080

  Bowles, Daniel W ^a,b   Mcdermott, Jessica D ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

c MET; EGFR; head and neck squamous cell carcinoma; Hedgehog; human papillomavirus; immunotherapy; Notch; PI3K; tyrosine kinase inhibitors

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AFATINIB; AMPHIREGULIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUPARLISIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DALANTERCEPT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; NEU DIFFERENTIATION FACTOR; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PACLITAXEL; PANITUMUMAB; PEMETREXED; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; ZALUTUMUMAB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; DRUG TREATMENT FAILURE; GENE DOSAGE; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84903194826     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.18     Document Type: Review

References (178)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013
3. Jemal A, Simard EP, Dorell C et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-Associated cancers and HPV vaccination coverage levels. J. Natl Cancer Inst. 105(3), 175-201 (2013
4. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113(7 Suppl.), 1980-1993 (2008
5. Schiffman M, Herrero R, Desalle R et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337(1), 76-84 (2005
6. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: Its role in pathogenesis and clinical implications. Clin. Cancer Res. 15(22), 6758-6762 (2009
7. Niedobitek G, Pitteroff S, Herbst H et al. Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. J. Clin. Pathol. 43(11), 918-921 (1990
8. Brachman DG, Graves D, Vokes E et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 52(17), 4832-4836 (1992
9. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356(19), 1944-1956 (2007
10. Mork J, Lie AK, Glattre E et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl J. Med. 344(15), 1125-1131 (2001
11. Gillison ML, D'souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst. 100(6), 407-420 (2008
12. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363(1), 24-35 (2010
13. Hong AM, Dobbins TA, Lee CS et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br. J. Cancer 103(10), 1510-1517 (2010
14. Huang SH, Perez-Ordonez B, Liu FF et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 276-283 (2012
15. Huang SH, Perez-Ordonez B, Weinreb I et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 49(1), 79-85 (2013
16. Keysar SB, Astling DP, Anderson RT et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol. Oncol. 7(4), 776-790 (2013
17. Kimple RJ, Harari PM, Torres AD et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin. Cancer Res. 19(4), 855-864 (2013
18. Lui VW, Hedberg ML, Li H et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3 (7), 761-769 (2013
19. Tentler JJ, Tan AC, Weekes CD et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9(6), 338-350 (2012
20. Pickering CR, Zhang J, Yoo SY et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 3(7), 770-781 2013
21. Stransky N, Egloff AM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046), 1157-1160 (2011
22. Agrawal N, Frederick MJ, Pickering CR et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046), 1154-1157 (2011
23. Morris LG, Kaufman AM, Gong Y et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet. 45(3), 253-261 (2013
24. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183-232 (1995
25. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21(14), 2787-2799 (2003
26. Kalyankrishna S, Grandis Jr. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24(17), 2666-2672 (2006
27. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53(15), 3579-3584 (1993
28. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62(24), 7350-7356 (2002
29. Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int. J. Cancer 120(8), 1731-1738 (2007
30. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12(17), 5064-5073 (2006
31. Tinhofer I, Klinghammer K, Weichert W et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin. Cancer Res. 17(15), 5197-5204 (2011
32. Jaiswal BS, Janakiraman V, Kljavin NM et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16(6), 463-474 (2009
33. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28(6), 1075-1083 (2010
34. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18(1), 77-82 (2006
35. Morris LG, Taylor BS, Bivona TG et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc. Natl Acad. Sci. USA 108(47), 19024-19029 (2011
36. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia 15(5), 461-471 (2013
37. Burgucu D, Guney K, Sahinturk D et al. Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer 12, 481 (2012
38. Bian Y, Hall B, Sun ZJ et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31(28), 3322-3332 (2012
39. Lechner M, Frampton G, Fenton T et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV-Tumors. Genome Med. 5(5), 49 (2013
40. Molinolo AA, Marsh C, El Dinali M et al. mTOR as a molecular target in HPV-Associated oral and cervical squamous carcinomas. Clin. Cancer Res. 18(9), 2558-2568 (2012
41. Herzog A, Bian Y, Broek RV et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-Type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin. Cancer Res. 19(14), 3808-3819 (2013
42. Holsinger FC, Piha-Paul SA, Janku F et al. Biomarker-directed therapy of squamous carcinomas of the head and neck: Targeting PI3K/PTEN/mTOR pathway. J. Clin. Oncol. 31(9), e137-e140 (2013
43. Fury MG, Sherman E, Ho AL et al. A Phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 119(10), 1823-1831 (2013
44. Fury MG, Sherman E, Ho A et al. A Phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother. Pharmacol. 70(1), 121-128 (2012
45. Bauman JE, Arias-Pulido H, Lee SJ et al. A Phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral. Oncol. 49(5), 461-467 (2013
46. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 12(12), 3657-3660 (2006
47. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22(4), 309-325 (2003
48. Saucier C, Khoury H, Lai KM et al. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc. Natl Acad. Sci. USA 101(8), 2345-2350 (2004
49. Murai M, Shen X, Huang L et al. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int. J. Oncol. 25(4), 831-840 (2004
50. Uchida D, Kawamata H, Omotehara F et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int. J. Cancer 93(4), 489-496 (2001
51. Kim CH, Moon SK, Bae JH et al. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 126(1), 88-94 (2006
52. Seiwert TY, Jagadeeswaran R, Faoro L et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69(7), 3021-3031 (2009
53. Aebersold DM, Landt O, Berthou S et al. Prevalence and clinical impact of Met Y1253D-Activating point mutation in radiotherapy-Treated squamous cell cancer of the oropharynx. Oncogene 22(52), 8519-8523 (2003
54. Knowles LM, Stabile LP, Egloff AM et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin. Cancer Res. 15(11), 3740-3750 (2009
55. Akervall J, Guo X, Qian CN et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin. Cancer Res. 10(24), 8204-8213 (2004
56. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007
57. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin. Cancer Res. 17(13), 4425-4438 (2011
58. Kerbel RS Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008
59. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: Biological and therapeutic implications. Lab. Invest. 88(4), 342-353 (2008
60. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18(10), 2046-2052 (2000
61. Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ. Res. 93(7), 682-689 (2003
62. Cunha SI, Pardali E, Thorikay M et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med. 207(1), 85-100 (2010
63. Chien CY, Chuang HC, Chen CH et al. The expression of activin receptor-like kinase 1 among patients with head and neck cancer. Otolaryngol. Head Neck Surg. 148(6), 965-973 (2013
64. Prince MEP, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J. Clin. Oncol. 26(17), 2871-2875 (2008
65. Young NR, Liu J, Pierce C et al. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol. Oncol. 7(3), 359-368 (2013
66. Malecki MJ, Sanchez-Irizarry C, Mitchell JL et al. Leukemia-Associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol. Cell Biol. 26(12), 4642-4651 (2006
67. Palomero T, Sulis ML, Cortina M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13(10), 1203-1210 (2007
68. Kolev V, Mandinova A, Guinea-Viniegra J et al. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell. Biol. 10(8), 902-911 (2008
69. Amaria RN, Bowles DW, Lewis KD, Jimeno A. Vismodegib in basal cell carcinoma. Drugs Today (Barc.) 48(7), 459-467 (2012
70. Jimeno A, Weiss GJ, Miller WH Jr et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 19(10), 2766-2774 (2013
71. Liu S, Dontu G, Mantle ID et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66(12), 6063-6071 (2006
72. Feldmann G, Dhara S, Fendrich V et al. Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 67(5), 2187-2196 (2007
73. Ohta H, Aoyagi K, Fukaya M et al. Cross talk between Hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-Type gastric cancers. Br. J. Cancer 100(2), 389-398 (2009
74. Lo HW, Hsu SC, Xia W et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 67(19), 9066-9076 (2007
75. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119(6), 1420-1428 (2009
76. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9(4), 265-273 (2009
77. Isohata N, Aoyagi K, Mabuchi T et al. Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. Int. J. Cancer 125(5), 1212-1221 (2009
78. Schnidar H, Eberl M, Klingler S et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res. 69(4), 1284-1292 (2009
79. Dormoy V, Danilin S, Lindner V et al. The sonic Hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol. Cancer 8, 123 (2009
80. Seto M, Ohta M, Asaoka Y et al. Regulation of the Hedgehog signaling by the mitogen-Activated protein kinase cascade in gastric cancer. Mol. Carcinog. 48(8), 703-712 (2009
81. Thayer SP, Di Magliano MP, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425(6960), 851-856 (2003
82. Clement V, Sanchez P, De Tribolet N, Radovanovic I, Ruiz I Altaba A. Hedgehog-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17(2), 165-172 (2007
83. Chung CH, Dignam JJ, Hammond ME et al. Glioma-Associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J. Clin. Oncol. 29(10), 1326-1334 (2011
84. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
85. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
86. Varilla V, Atienza J, Dasanu CA. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin. Biol. Ther. 13(9), 1241-1256 (2013
87. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J. Clin. Oncol. 29(36), 4828-4836 (2011
88. Turksma AW, Braakhuis BJ, Bloemena E, Meijer CJ, Leemans CR, Hooijberg E. Immunotherapy for head and neck cancer patients: Shifting the balance. Immunotherapy 5(1), 49-61 (2013
89. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: A review. Clin. Dev. Immunol. 2010, 701657 (2010
90. Gastman BR, Atarshi Y, Reichert TE et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59(20), 5356-5364 (1999
91. Kassouf N, Thornhill MH. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-Alpha, to induce apoptosis in Jurkat T cells: Possible mechanisms for immune escape by head and neck cancers. Oral Oncol. 44(7), 672-682 (2008
92. Badoual C, Hans S, Rodriguez J et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12(2), 465-472 (2006
93. Chikamatsu K, Sakakura K, Whiteside TL, Furuya N. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 29(2), 120-127 (2007
94. Bergmann C, Strauss L, Wang Y et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 14(12), 3706-3715 (2008
95. Wild CA, Brandau S, Lindemann M et al. Toll-like receptors in regulatory T cells of patients with head and neck cancer. Arch Otolaryngol. Head Neck Surg. 136(12), 1253-1259 (2010
96. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 8, 10 (2008
97. Tartour E, Mosseri V, Jouffroy T et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 357(9264), 1263-1264 (2001
98. Schuler PJ, Borger V, Bolke E et al. Dendritic cell generation and CD4+ CD25high FOXP3+ regulatory t cells in human head and neck carcinoma during radio-chemotherapy. Eur. J. Med. Res. 16(2), 57-62 (2011
99. Brocks CP, Pries R, Frenzel H, Ernst M, Schlenke P, Wollenberg B. Functional alteration of myeloid dendritic cells through head and neck cancer. Anticancer Res. 27(2), 817-824 (2007
100. Molling JW, Langius JA, Langendijk JA et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25(7), 862-868 (2007
101. Kreimer AR, Johansson M, Waterboer T et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol. 31(21), 2708-2715 (2013
102. Thurlow JK, Pena Murillo CL, Hunter KD et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J. Clin. Oncol. 28(17), 2881-2888 (2010
103. Kong CS, Narasimhan B, Cao H et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 74(2), 553-561 (2009
104. Lyford-Pike S, Peng S, Young GD et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-Associated head and neck squamous cell carcinoma. Cancer Res. 73(6), 1733-1741 (2013
105. Badoual C, Hans S, Merillon N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-Associated head and neck cancer. Cancer Res. 73(1), 128-138 (2013
106. Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer (ELAN-UNFIT). http://clinicaltrials.gov/show/NCT01884623
107. A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck. http://clinicaltrials.gov/ct2/show/ NCT01577173
108. A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer. http://clinicaltrials.gov/ct2/show/ NCT01598077
109. LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy. http://clinicaltrials.gov/ct2/show/ NCT01345682
110. LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy. http://clinicaltrials.gov/ct2/show/ NCT01345669
111. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311-1318 (1995
112. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int. J. Radiat Oncol. Biol. Phys. 49(2), 427-433 (2001
113. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006
114. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11(1), 21-28 (2010
115. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25(16), 2171-2177 (2007
116. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008
117. Licitra L, Storkel S, Kerr KM et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur. J. Cancer 49(6), 1161-1168 (2013
118. Nagel R, Martens-De Kemp SR, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol. 49(6), 560-566 (2013
119. Koutcher L, Sherman E, Fury M et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-And-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 81(4), 915-922 (2011
120. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28(43), 3801-3813 (2009
121. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47(8), 1231-1243 (2011
122. Rebucci M, Peixoto P, Dewitte A et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: Role of AKT inhibition in bypassing this resistance. Int. J. Oncol. 38(1), 189-200 (2011
123. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007
124. Huang S, Li C, Armstrong EA et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73(2), 824-833 (2013
125. Yoshikawa M, Tsuchihashi K, Ishimoto T et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-Targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 73(6), 1855-1866 (2013
126. Mandal M, Myers JN, Lippman SM et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: Association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112(9), 2088-2100 (2008
127. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label Phase 3 randomised trial. Lancet Oncol. 14(8), 697-710 (2013
128. Machiels JP, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised Phase 3 trial. Lancet Oncol. 12(4), 333-343 (2011
129. Takikita M, Xie R, Chung JY et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J. Transl. Med. 9, 126 (2011
130. Shames DS, Carbon J, Walter K et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS ONE 8(2), e56765 (2013
131. Schaefer G, Haber L, Crocker LM et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20(4), 472-486 (2011
132. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012
133. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85 (2004
134. Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol. 25(16), 2178-2183 (2007
135. Martins RG, Parvathaneni U, Bauman JE et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized Phase II trial. J. Clin. Oncol. 31(11), 1415-1421 (2013
136. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009
137. Stewart JS, Cohen EE, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol. 27(11), 1864-1871 (2009
138. Argiris A, Ghebremichael M, Gilbert J et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncology Group trial J. Clin. Oncol. 31(11), 1405-1414 (2013
139. De Souza JA, Davis DW, Zhang Y et al. A Phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 18(8), 2336-2343 (2012
140. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther 343(2), 342-350 (2012
141. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008
142. Seiwert T, Fayette J, Cupissol D et al. A randomized, open-label, Phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck-final data Presented at: Multidisciplinary Head and Neck Cancer Symposium. AZ, USA, 26-28 January 2012
143. Cupissol D, Seiwert TY, Fayette J. et al. A randomized, open-label, Phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover. J. Clin. Oncol. 31, Abstract 6001 (2013
144. Ather F, Hamidi H, Fejzo MS et al. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS ONE 8(2), e56112 (2013
145. Abdul Razak AR, Soulieres D, Laurie SA et al. A Phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann. Oncol. 24(3), 761-769 (2013
146. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin. Investig. Drugs 20(4), 507-518 (2011
147. Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30(3), 282-290 (2012
148. Hong DS, Bowles DW, Falchook GS et al. A multicenter Phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 18(15), 4173-4182 (2012
149. Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery. http://clinicaltrials.gov/ct2/show/ NCT01696955
150. Oral Rigosertib for Squamous Cell Carcinoma. http://clinicaltrials.gov/ ct2/show/ NCT01807546
151. Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (PIK-ORL). http://clinicaltrials.gov/ct2/show/ NCT01737450
152. PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. http://clinicaltrials.gov/ct2/show/ NCT01816984
153. A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. http://clinicaltrials.gov/ct2/show/ NCT01602315
154. Phase 1 and 2 Study of PX-866 and Cetuximab. http://clinicaltrials.gov/ ct2/show/ NCT01252628
155. Study of PX-866 and Docetaxel in Solid Tumors. http://clinicaltrials.gov/ ct2/show/ NCT01204099
156. Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. http://clinicaltrials.gov/ct2/show/ NCT01349933
157. Fury MG, Lee NY, Sherman E et al. A Phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 118(20), 5008-5014 (2012
158. Argiris A, Karamouzis MV, Gooding WE et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J. Clin. Oncol. 29(9), 1140-1145 (2011
159. Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. http://clinicaltrials.gov/ct2/ show/ NCT00588770
160. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res. 61(13), 5090-5101 (2001
161. Cohen EE, Davis DW, Karrison TG et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A Phase I/II study. Lancet Oncol. 10(3), 247-257 (2009
162. Argiris A, Kotsakis AP, Hoang T et al. Cetuximab and bevacizumab: Preclinical data and Phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 24(1), 220-225 (2013
163. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 117(26), 6999-7006 (2011
164. Bendell JC, Gordon M, Hurwitz H et al. A Phase 1 dose escalating study with ACE-041, a novel inhibitor of ALK1 mediated angiogenesis, in patients with advanced solid tumors Presented at: AACR 102nd Annual Meeting 2011. FL, USA, 2-6 April 2011
165. Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck. http://clinicaltrials.gov/ct2/show/ NCT01458392
166. Keysar SB, Le PN, Anderson RT et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 73(11), 3381-3392 (2013
167. Wong YK, Chang KW, Cheng CY, Liu CJ. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J. Oral Pathol. Med. 35(1), 51-54 (2006
168. ClinicalTrials.gov. www.clinicaltrials.gov
169. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
170. Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol. Immunother. 62(8), 1347-1357 (2013
171. Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J. Lm-LLO-based immunotherapies and HPV-Associated disease. J. Oncol. 2012, 542851 (2012
172. Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer (REALISTIC:). http://clinicaltrials.gov/ ct2/show/ NCT01598792
173. Best SR, Peng S, Juang CM et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared with intramuscular injection and intradermal gene gun delivery. Vaccine 27(40), 5450-5459 (2009
174. Bagarazzi ML, Yan J, Morrow MP et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci. Transl. Med. 4(155), 155ra138 (2012
175. O'sullivan B, Huang SH, Siu LL et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 31(5), 543-550 (2013
176. Herrero R, Quint W, Hildesheim A et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8(7), e68329 (2013
177. Janku F, Wheler JJ, Naing A et al. PIK3CA mutations in advanced cancers: Characteristics and outcomes. Oncotarget 3(12), 1566-1575 (2012
178. Janku F, Wheler JJ, Westin SN et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30(8), 777-782 (2012.